ChAdOx1 nCoV-19 (AZD1222) protects Syrian hamsters against SARS-CoV-2 B.1.351 and B.1.1.7-Reference-Cited by-同舟云学术

ChAdOx1 nCoV-19 (AZD1222) protects Syrian hamsters against SARS-CoV-2 B.1.351 and B.1.1.7

Published:2021-10-07 Issue:1 Volume:12 Page:
ISSN:2041-1723
Container-title:Nature Communications
language:en
Short-container-title:Nat Commun

Author:

Fischer Robert J.,van Doremalen Neeltje^ORCID,Adney Danielle R.,Yinda Claude Kwe,Port Julia R.,Holbrook Myndi G.^ORCID,Schulz Jonathan E.,Williamson Brandi N.,Thomas Tina,Barbian Kent,Anzick Sarah L.,Ricklefs Stacy,Smith Brian J.,Long Dan,Martens Craig,Saturday Greg,de Wit Emmie^ORCID,Gilbert Sarah C.^ORCID,Lambe Teresa^ORCID,Munster Vincent J.^ORCID

Abstract

AbstractWe investigated ChAdOx1 nCoV-19 (AZD1222) vaccine efficacy against SARS-CoV-2 variants of concern (VOCs) B.1.1.7 and B.1.351 in Syrian hamsters. We previously showed protection against SARS-CoV-2 disease and pneumonia in hamsters vaccinated with a single dose of ChAdOx1 nCoV-19. Here, we observe a 9.5-fold reduction of virus neutralizing antibody titer in vaccinated hamster sera against B.1.351 compared to B.1.1.7. Vaccinated hamsters challenged with B.1.1.7 or B.1.351 do not lose weight compared to control animals. In contrast to control animals, the lungs of vaccinated animals do not show any gross lesions. Minimal to no viral subgenomic RNA (sgRNA) and no infectious virus can be detected in lungs of vaccinated animals. Histopathological evaluation shows extensive pulmonary pathology caused by B.1.1.7 or B.1.351 replication in the control animals, but none in the vaccinated animals. These data demonstrate the effectiveness of the ChAdOx1 nCoV-19 vaccine against clinical disease caused by B.1.1.7 or B.1.351 VOCs.

Funder

Division of Intramural Research, National Institute of Allergy and Infectious Diseases

Publisher

Springer Science and Business Media LLC

Subject

General Physics and Astronomy,General Biochemistry, Genetics and Molecular Biology,General Chemistry

Link

https://www.nature.com/articles/s41467-021-26178-y.pdf

Reference34 articles.

1. Chand, M. et al. Investigation of Novel SARS-COV-2 variant Variant of Concern 202012/01 https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/959361/Technical_Briefing_VOC202012-2_Briefing_2.pdf (2020).

2. Davies, N. G. et al. Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England. Science https://doi.org/10.1126/science.abg3055 (2021).

3. Tegally, H. et al. Emergence And Rapid Spread of a New Severe Acute Respiratory Syndrome-Related Coronavirus 2 (SARS-CoV-2) Lineage with Multiple Spike Mutations in South Africa. https://doi.org/10.1101/2020.12.21.20248640 (2020).

4. van Doremalen, N. et al. Intranasal ChAdOx1 nCoV-19/AZD1222 Vaccination Reduces Shedding of SARS-CoV-2 D614G in Rhesus Macaques. https://doi.org/10.1101/2021.01.09.426058 (2021).

5. Port, J. R. et al. SARS-CoV-2 Disease Severity and Transmission Efficiency is Increased for Airborne But Not Fomite Exposure in Syrian Hamsters.https://doi.org/10.1101/2020.12.28.424565 (2020).

Cited by 50 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Design, Immunogenicity and Preclinical Efficacy of the ChAdOx1.COVconsv12 Pan-Sarbecovirus T-Cell Vaccine;Vaccines;2024-08-26

2. Mammalian cell expressed recombinant trimeric spike protein is a potent vaccine antigen and confers near-complete protection against SARS-CoV-2 infection in Hamster;Vaccine;2024-08

3. Intranasal SARS-CoV-2 Omicron variant vaccines elicit humoral and cellular mucosal immunity in female mice;eBioMedicine;2024-07

4. Hamster Model of Severe COVID-19 Demonstrates Differential Efficacy of first Licensed Western Vaccines in the Absence of Immunopathogenesis;2024-04-24

5. Augmentation of Omicron BA.1 pathogenicity in hamsters using intratracheal inoculation;npj Viruses;2024-01-16